Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3423431 | 0.98 | GAA (0.57) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL19513827 | 0.82 | GAA (0.39) | GAANPSR1ATM | |
| SCHEMBL29956161 | 0.81 | GAA (0.38) | GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3299204 | 0.78 | GAA (0.54) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL14586465 | 0.76 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL3817278 | 0.76 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL13049649 | 0.76 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL18380993 | 0.74 | GAA (0.62) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL896479 | 0.74 | GAA (1.00) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL28272374 | 0.73 | GAA (0.43) | GAANPSR1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | claimed |
| US-11179335-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2021-11-23 | — | — | US | claimed |
| US-10517823-B1 | ROS—responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2019-12-31 | — | — | US | claimed |
| EP-4702025-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001884-A1 | Heterocycle compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4554679-A1 | HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-21 | — | — | EP | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20060194811-A1 | Pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1663973-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1595869-A1 | PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005026123-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-5576429-A | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRICIDE; ANTITUMOR AGENT | MEDIVIR AB (SE) | 1996-11-19 | — | — | US | disclosed |
| US-5440040-A | Drug for Aids therapy; viricides | MEDIVIR AB (SE) | 1995-08-08 | — | — | US | disclosed |
| WO-1989012061-A1 | PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES | MEDIVIR AB (SE) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001884-A1 | Heterocycle compounds for the treatment of cancer | ADORA1, ADORA2A, ADORA3 | GAA 4076/4885NPSR1 599/4885ATM 1857/4885 |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | GAA 2929/4885NPSR1 1686/4885ATM 3346/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | GAA 252/4885NPSR1 1497/4885ATM 2703/4885 |
| US-20060194811-A1 | Pyrimidine derivatives | ADORA3, NR4A1, NR0B1 | GAA 4620/4885NPSR1 21/4885ATM 2684/4885 |
| US-20250270174-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | GAA 569/4885NPSR1 250/4885ATM 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.